ALNY
Alnylam Pharmaceuticals, Inc.
Revenue to net incomeLast 12 months
Key figures
| Metric | Last 12 months | 5-year CAGR |
|---|---|---|
| Revenue | $5.0B | +49.8% |
| Gross profit | $3.9B | +48.9% |
| Operating income | $978M | — |
| Net income | $2.6B | — |
| EPS | $19.23 | — |
| Free cash flow | $752M | — |
Alnylam Pharmaceuticals, Inc.
| Metric | Last 12 months | 5-year CAGR |
|---|---|---|
| Revenue | $5.0B | +49.8% |
| Gross profit | $3.9B | +48.9% |
| Operating income | $978M | — |
| Net income | $2.6B | — |
| EPS | $19.23 | — |
| Free cash flow | $752M | — |